Cargando…
The JmjN domain as a dimerization interface and a targeted inhibitor of KDM4 demethylase activity
Histone methylation is regulated to shape the epigenome by modulating DNA compaction, thus playing central roles in fundamental chromatin-based processes including transcriptional regulation, DNA repair and cell proliferation. Histone methylation is erased by demethylases including the well-establis...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908291/ https://www.ncbi.nlm.nih.gov/pubmed/29682190 http://dx.doi.org/10.18632/oncotarget.24717 |
_version_ | 1783315694617624576 |
---|---|
author | Levin, May Stark, Michal Assaraf, Yehuda G. |
author_facet | Levin, May Stark, Michal Assaraf, Yehuda G. |
author_sort | Levin, May |
collection | PubMed |
description | Histone methylation is regulated to shape the epigenome by modulating DNA compaction, thus playing central roles in fundamental chromatin-based processes including transcriptional regulation, DNA repair and cell proliferation. Histone methylation is erased by demethylases including the well-established KDM4 subfamily members, however, little is known about their dimerization capacity and its impact on their demethylase activity. Using the powerful bimolecular fluorescence complementation technique, we herein show the in situ formation of human KDM4A and KDM4C homodimers and heterodimers in nuclei of live transfectant cells and evaluate their H3K9me3 demethylation activity. Using size exclusion HPLC as well as Western blot analysis, we show that endogenous KDM4C undergoes dimerization under physiological conditions. Importantly, we identify the JmjN domain as the KDM4C dimerization interface and pin-point specific charged residues therein to be essential for this dimerization. We further demonstrate that KDM4A/C dimerization is absolutely required for their demethylase activity which was abolished by the expression of free JmjN peptides. In contrast, KDM4B does not dimerize and functions as a monomer, and hence was not affected by free JmjN expression. KDM4 proteins are overexpressed in numerous malignancies and their pharmacological inhibition or depletion in cancer cells was shown to impair tumor cell proliferation, invasion and metastasis. Thus, the KDM4 dimer-interactome emerging from the present study bears potential implications for cancer therapeutics via selective inhibition of KDM4A/C demethylase activity using JmjN-based peptidomimetics. |
format | Online Article Text |
id | pubmed-5908291 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-59082912018-04-20 The JmjN domain as a dimerization interface and a targeted inhibitor of KDM4 demethylase activity Levin, May Stark, Michal Assaraf, Yehuda G. Oncotarget Research Paper Histone methylation is regulated to shape the epigenome by modulating DNA compaction, thus playing central roles in fundamental chromatin-based processes including transcriptional regulation, DNA repair and cell proliferation. Histone methylation is erased by demethylases including the well-established KDM4 subfamily members, however, little is known about their dimerization capacity and its impact on their demethylase activity. Using the powerful bimolecular fluorescence complementation technique, we herein show the in situ formation of human KDM4A and KDM4C homodimers and heterodimers in nuclei of live transfectant cells and evaluate their H3K9me3 demethylation activity. Using size exclusion HPLC as well as Western blot analysis, we show that endogenous KDM4C undergoes dimerization under physiological conditions. Importantly, we identify the JmjN domain as the KDM4C dimerization interface and pin-point specific charged residues therein to be essential for this dimerization. We further demonstrate that KDM4A/C dimerization is absolutely required for their demethylase activity which was abolished by the expression of free JmjN peptides. In contrast, KDM4B does not dimerize and functions as a monomer, and hence was not affected by free JmjN expression. KDM4 proteins are overexpressed in numerous malignancies and their pharmacological inhibition or depletion in cancer cells was shown to impair tumor cell proliferation, invasion and metastasis. Thus, the KDM4 dimer-interactome emerging from the present study bears potential implications for cancer therapeutics via selective inhibition of KDM4A/C demethylase activity using JmjN-based peptidomimetics. Impact Journals LLC 2018-03-30 /pmc/articles/PMC5908291/ /pubmed/29682190 http://dx.doi.org/10.18632/oncotarget.24717 Text en Copyright: © 2018 Levin et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Paper Levin, May Stark, Michal Assaraf, Yehuda G. The JmjN domain as a dimerization interface and a targeted inhibitor of KDM4 demethylase activity |
title | The JmjN domain as a dimerization interface and a targeted inhibitor of KDM4 demethylase activity |
title_full | The JmjN domain as a dimerization interface and a targeted inhibitor of KDM4 demethylase activity |
title_fullStr | The JmjN domain as a dimerization interface and a targeted inhibitor of KDM4 demethylase activity |
title_full_unstemmed | The JmjN domain as a dimerization interface and a targeted inhibitor of KDM4 demethylase activity |
title_short | The JmjN domain as a dimerization interface and a targeted inhibitor of KDM4 demethylase activity |
title_sort | jmjn domain as a dimerization interface and a targeted inhibitor of kdm4 demethylase activity |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908291/ https://www.ncbi.nlm.nih.gov/pubmed/29682190 http://dx.doi.org/10.18632/oncotarget.24717 |
work_keys_str_mv | AT levinmay thejmjndomainasadimerizationinterfaceandatargetedinhibitorofkdm4demethylaseactivity AT starkmichal thejmjndomainasadimerizationinterfaceandatargetedinhibitorofkdm4demethylaseactivity AT assarafyehudag thejmjndomainasadimerizationinterfaceandatargetedinhibitorofkdm4demethylaseactivity AT levinmay jmjndomainasadimerizationinterfaceandatargetedinhibitorofkdm4demethylaseactivity AT starkmichal jmjndomainasadimerizationinterfaceandatargetedinhibitorofkdm4demethylaseactivity AT assarafyehudag jmjndomainasadimerizationinterfaceandatargetedinhibitorofkdm4demethylaseactivity |